Loftyrock Investment

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Galux specializes in molecular design technology aimed at discovering and developing innovative drugs for incurable and rare diseases. The company employs an AI-based drug design platform that integrates principles from artificial intelligence, physics, and chemistry. This technology allows Galux to design a variety of biomolecules, ranging from small molecules to peptides and larger proteins. By focusing on attractive biological targets, Galux seeks to provide healthcare professionals with effective treatments for conditions that currently lack viable therapeutic options.